Clinical trial NCT00378391: European Registry on STEMI Patients Transferred for PCI With Upstream Use of Abciximab - EuroTransfer Registry
Official title: European Registry on Patients With ST-Elevation MI Transferred for Mechanical Reperfusion (PCI)With a Special Focus on Upstream Use of Abciximab
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: ST-Elevation Myocardial Infarction
Acute Coronary Syndrome
Keywords: ST-Elevation Myocardial Infarction
upstream abciximab
guideline adherence
hospital networking
Lead sponsor: Jagiellonian University
Sponsor class: OTHER
Collaborators: name: Foundation for Medical Research in Krakow, Poland
First posted: 2006-09-20
Enrollment: 1800
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: DEFINED_POPULATION
Time perspective: OTHER

Brief summary: EUROTRANSFER Registry is a prospective, international, web-based European Registry on Patients with ST-Elevation MI Transferred for Mechanical Reperfusion (PCI) with a Special Focus on Upstream Use of Abciximab.

This registry is designed to collect data on approximately 1800 patients during a 12 month enrollment period in up to 20 interventional cardiology centres with hospital transfer networks from all over Europe.

Analysis of this registry should allow to monitor transfer timelines of patients arriving to the cath-lab from the regional hospital with or without upstream start of abciximab and scheduled for mechanical reperfusion (PCI) as well as to monitor regional differences across Europe in regard to the impact that time of various stages of the treatment chain may have on clinical outcomes.


Eligibility criteria: Inclusion Criteria:

PATIENTS:

* All consecutive STEMI patients \>=18years arriving to the Cath Lab hospital (invasive facility center) from transfer.

  * Transfer with respect to this registry is defined as patients that reach the Cath Lab hospital:

    1. transferred from a surrounding regional community hospitals that the Cath Lab hospital has an established referral pattern with or
    2. after being picked-up by an ambulance which is equipped/staffed to provide specific medical therapy (like prehospital thrombolysis or upstream abciximab). Usually these have a physician or specifically trained nurse on board.

       CENTRES:
  * Provide 24 hour/7 days on duty PCI service.
  * Has an established regional hospital referral network with \>=8 patients/month arriving from transfer (as defined above).
  * A rate of \>=10% of these transfer patients who receive upstream abciximab before or during transfer to the Cath Lab hospital. Start of abciximab in the ER or CCU of the Cath Lab hospital will not be considered as upstream start of abciximab.

Exclusion Criteria:

* Patients who arrive to the Cath Lab from other pathways than those specified above (a. and b.), e.g. those who come by ambulances that do not provide specific medical therapy or arrive directly to the ER of the Cath Lab hospital by own feet/car will not be included in this registry.
* Patients from controlled clinical trials shall be included as long as their actual treatment is fully known. Thus, participants from randomized trials with blinded treatment cannot be included in this registry.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Helsinki
country: Finland
facility: Helsinki University Central Hospital
city: Villingen
country: Germany
facility: Schwarzwald-Baar Klinikum Villingen-Schwenningen GmbH
city: Arezzo
country: Italy
facility: San Donato Hospital
city: Mantova
country: Italy
facility: Ospedale Carlo Poma
city: Massa
country: Italy
facility: Ospedale G.Pasquinucci
city: Reggio Emilia
country: Italy
facility: Santa Maria Nuova Hospital Reggio Emilia
city: Treviso
country: Italy
facility: Ospedale S.Maria di Ca Foncello
city: Krakow
country: Poland
facility: Cardiac Catheterization Laboratories Jagiellonian University Medical College, University Hospital
city: Krakow
country: Poland
facility: Department of Interventional Cardiology, John Paul II Hospital
city: Przemysl
country: Poland
facility: Szpital Wojewodzki w Przemyslu
city: Tarnow
country: Poland
facility: Szpital im. Szczeklika Tarnow
city: Ljubljana
country: Slovenia
facility: University Medical Center Ljubljana
city: Coruna
country: Spain
facility: Hospital Juan Canalejo
city: Santiago de Compostela
country: Spain
facility: Hospital Clinico Universitario
city: Linköping
country: Sweden
facility: Linköping University Hospital
Study officials:
affiliation: Cardiac Catheterization Laboratories, Jagiellonian University Medical College
name: Dariusz Dudek, Assoc. Prof.
role: PRINCIPAL_INVESTIGATOR
affiliation: Cardiac Catheterization Laboratories, Jagiellonian University Medical College
name: Zbigniew Siudak, MD
role: STUDY_CHAIR
affiliation: KCRI
name: Lukasz Partyka, MD, PhD
role: STUDY_DIRECTOR
References:
citation: Dziewierz A, Siudak Z, Rakowski T, Kleczynski P, Zasada W, Dubiel JS, Dudek D. Impact of direct stenting on outcome of patients with ST-elevation myocardial infarction transferred for primary percutaneous coronary intervention (from the EUROTRANSFER registry). Catheter Cardiovasc Interv. 2014 Nov 15;84(6):925-31. doi: 10.1002/ccd.25266. Epub 2014 Jul 29.
citation: Dziewierz A, Siudak Z, Rakowski T, Kleczynski P, Dubiel JS, Dudek D. Early administration of abciximab reduces mortality in female patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention (from the EUROTRANSFER Registry). J Thromb Thrombolysis. 2013 Oct;36(3):240-6. doi: 10.1007/s11239-012-0826-3.
citation: Dziewierz A, Mielecki W, Siudak Z, Rakowski T, Janzon M, Birkemeyer R, Zasada W, Dubiel JS, Dudek D. Early abciximab administration before primary percutaneous coronary intervention improves clinical outcome in diabetic patients with ST-segment elevation myocardial infarction (EUROTRANSFER Registry). Atherosclerosis. 2012 Jul;223(1):212-8. doi: 10.1016/j.atherosclerosis.2012.04.018. Epub 2012 May 15.
citation: Siudak Z, Zawislak B, Dziewierz A, Rakowski T, Jakala J, Bartus S, Noworolnik B, Zasada W, Dubiel JS, Dudek D. Transradial approach in patients with ST-elevation myocardial infarction treated with abciximab results in fewer bleeding complications: data from EUROTRANSFER registry. Coron Artery Dis. 2010 Aug;21(5):292-7. doi: 10.1097/MCA.0b013e32833aa6d1.
citation: Dudek D, Siudak Z, Janzon M, Birkemeyer R, Aldama-Lopez G, Lettieri C, Janus B, Wisniewski A, Berti S, Olivari Z, Rakowski T, Partyka L, Goedicke J, Zmudka K; EUROTRANSFER Registry Investigators. European registry on patients with ST-elevation myocardial infarction transferred for mechanical reperfusion with a special focus on early administration of abciximab -- EUROTRANSFER Registry. Am Heart J. 2008 Dec;156(6):1147-54. doi: 10.1016/j.ahj.2008.08.004. Epub 2008 Oct 19.